カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

ファーマコゲノミクス（PGx）のグローバル市場予測（～2028）：キット、試薬

■ 英語タイトル：Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：BT8937-24）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：BT8937-24
■ 発行日：2024年2月14日
■ 調査対象地域：グローバル
■ 産業分野：バイオテクノロジー
■ ページ数：381
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[ファーマコゲノミクス（PGx）のグローバル市場予測（～2028）：キット、試薬]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

"ファーマコゲノミクス（PGx）市場は、2023年の推定35億米ドルから2028年には58億米ドルに達すると予測され、予測期間中の年平均成長率は10.6%" この市場の成長は、創薬と薬剤開発を目的とした研究開発努力と、個別化された医薬品への注目の高まりに起因しています。

"2022年の製品・サービス別シェアはキット&試薬セグメントが最大"
2022年、世界のファーマコゲノミクス（PGx）市場では、キット＆試薬セグメントが製品タイプ別で最大のシェアを占めました。ゲノミクス研究のための高品質な試薬への需要の高まり、個別化医薬品の開発への注目の高まり、ゲノミクス分野における研究プロジェクトの増加などの要因が、この市場の成長を促進しています。

"2023〜2028年の予測期間中、ファーマコゲノミクス（PGx）市場ではアジア太平洋地域が成長"
アジア太平洋地域は予測期間中に最も高い成長率で成長する見込みです。高度なシーケンス技術の採用拡大や医療分野の活況など、さまざまな要因が同地域のファーマコゲノミクス（PGx）市場の成長を後押ししています。
ヘルスケア分野の発展を目的とした製薬企業やバイオテクノロジー企業からの資金提供や投資の増加は、アジア太平洋地域におけるファーマコゲノミクス（PGx）市場の成長を促進すると期待されています。R&Dマガジンによると、アジアは研究開発（R&D）投資において世界一の地域となっており、世界のR&Dシェアの44%以上を占めています。同地域は毎年着実に半数以上のシェアを獲得しており、この傾向が続けば、2030年までに研究開発投資全体の半分以上を占めるようになるかもしれません。中国はR&Dインフラと人材能力を積極的に強化し、支出、野心、長期計画への一貫したコミットメントを維持しています。これらの要因は、2023年から2028年にかけて、この地域で最も高いCAGRに寄与すると予想されます。

本レポートのために実施した一次インタビューは以下のように分類されます。

- 回答者別：供給側70％、需要側30%
- 役職別：管理職：45%、CXOおよび取締役：30%、経営幹部：25%
- 地域別：北米30％、欧州20％、アジア太平洋地域30％、中南米15％、中東・アフリカ5%

レポート掲載企業リスト
• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• Eurofins Scientific (Luxembourg)
• Bio-Rad Laboratories, Inc. (US)
• Agilent Technologies, Inc. (US)
• BD (US)
• QIAGEN (Netherlands)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Revvity (US), IQVIA Inc. (US)
• Mesa Labs, Inc. (US)
• Medpace (US)
• MGI Tech Co., Ltd. (China)
• Takara Bio Inc. (Japan)
• PacBio (US)
• New England Biolabs (US)
• BGI (China), Novogene Co., Ltd. (China)
• SOPHiA GENETICS (Switzerland), Fios Genomics (UK)
• Personalis, Inc. (US)
• BioAI Health Inc. (US)
• NeoGenomics Laboratories (US)
• Macrogen, Inc. (South Korea).)

調査範囲
この調査レポートは、ファーマコゲノミクス（PGx）市場を製品＆サービス（キット＆試薬（シーケンスキット＆試薬、PCRキット＆試薬、マイクロアレイキット＆試薬、その他のキット＆試薬）およびサービス）、技術（シーケンス、PCR、マイクロアレイ、その他の技術）、疾患領域（がん、 心血管疾患、神経疾患、その他の疾患領域）、アプリケーション（個別化医療、臨床研究、創薬・前臨床開発）、エンドユーザー（学術・研究機関、製薬・バイオテクノロジー企業、開発業務受託機関）に分類しています。
本レポートでは、ファーマコゲノミクス（PGx）市場の成長に影響を与える重要な要因（促進要因、動向、課題、機会など）について詳細な情報を提供しています。主要な業界プレイヤーを徹底的に分析し、そのビジネスプロフィール、製品/サービス、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。さらに、本レポートは、ファーマコゲノミクス（PGx）市場における新製品の発売、合併、買収などの最近の動向を網羅しています。

レポート購入の主な利点
本レポートは、ファーマコゲノミクス（PGx）市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。

本レポートは、以下のポイントに関する洞察を提供します。
-市場の成長に影響を与える主要な促進要因（慢性疾患および遺伝性疾患の罹患率および有病率の増加、ゲノムプロジェクトを支援するための投資および資金の増加）、阻害要因（データの統合および解釈における課題、薬剤反応のばらつきに関する問題）、機会（専門化/個別化医療におけるゲノミクスの利用拡大）、および課題（倫理的および規制上の問題、患者のプライバシーおよびデータアクセシビリティに関する懸念）に関する分析を提供します。
-製品・サービスの開発/革新：ファーマコゲノミクス（PGx）市場で新たに発売された製品/サービスに関する詳細な洞察を提供します。
-市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域の市場を分析しています。
-市場の多様化：新製品/サービス、未開拓の地域、最近の開発、ファーマコゲノミクス（PGx）市場における投資に関する詳細な情報を提供します。
-競合評価：Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US)などの企業があります。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 ファーマコゲノミクス（PGx）の世界市場規模：製品・サービス別
7 ファーマコゲノミクス（PGx）の世界市場規模：技術別
8 ファーマコゲノミクス（PGx）の世界市場規模：用途別
9 ファーマコゲノミクス（PGx）の世界市場規模：疾患領域別
10 ファーマコゲノミクス（PGx）の世界市場規模：エンドユーザー別
11 ファーマコゲノミクス（PGx）の世界市場規模：地域別
12 競争状況
13 企業情報
14 付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 47
1.1 STUDY OBJECTIVES 47
1.2 MARKET DEFINITION 47
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 48
1.2.2 MARKET SEGMENTATION 49
FIGURE 1 PHARMACOGENOMICS MARKET SCOPE 49
1.2.3 YEARS CONSIDERED 50
1.3 CURRENCY 50
1.4 STAKEHOLDERS 50
1.5 LIMITATIONS 51
1.6 RECESSION IMPACT 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
FIGURE 2 RESEARCH DESIGN 52
2.1.1 SECONDARY DATA 53
2.1.2 PRIMARY DATA 54
FIGURE 3 PHARMACOGENOMICS MARKET: BREAKDOWN OF PRIMARIES 54
2.2 MARKET SIZE ESTIMATION 55
2.2.1 BOTTOM-UP APPROACH 55
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022) 55
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 56
FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022) 56
2.2.1.1 Insights from primaries 58
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 58
2.2.2 TOP-DOWN APPROACH 58
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 58
2.3 GROWTH FORECAST 60
FIGURE 9 PHARMACOGENOMICS MARKET: CAGR PROJECTIONS 60
FIGURE 10 PHARMACOGENOMICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 62
FIGURE 11 DATA TRIANGULATION METHODOLOGY 62
2.5 RESEARCH ASSUMPTIONS 63
2.6 RISK ANALYSIS 63
2.7 RECESSION IMPACT ANALYSIS 63
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 63
TABLE 2 US: HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 64
TABLE 3 US: HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 64
3 EXECUTIVE SUMMARY 65
FIGURE 12 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 65
FIGURE 13 PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 66
FIGURE 14 PHARMACOGENOMICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 66
FIGURE 15 PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD MILLION) 67
FIGURE 16 PHARMACOGENOMICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 68
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF PHARMACOGENOMICS MARKET 69
4 PREMIUM INSIGHTS 70
4.1 PHARMACOGENOMICS MARKET OVERVIEW 70
FIGURE 18 RISING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH 70
4.2 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022) 71
FIGURE 19 KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN PHARMACOGENOMICS MARKET IN 2022 71
4.3 PHARMACOGENOMICS MARKET SHARE, BY TECHNOLOGY, 2022 71
FIGURE 20 SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 71
4.4 PHARMACOGENOMICS MARKET SHARE, BY APPLICATION, 2022 72
FIGURE 21 PERSONALIZED MEDICINE SEGMENT DOMINATED MARKET IN 2022 72
4.5 PHARMACOGENOMICS MARKET SHARE, BY DISEASE AREA, 2022 72
FIGURE 22 CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF PHARMACOGENOMICS MARKET IN 2022 72
4.6 PHARMACOGENOMICS MARKET SHARE, BY END USER, 2022 73
FIGURE 23 ACADEMIC & RESEARCH INSTITUTES SEGMENT DOMINATED MARKET IN 2022 73
4.7 PHARMACOGENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 73
FIGURE 24 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
FIGURE 25 PHARMACOGENOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 74
TABLE 4 PHARMACOGENOMICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
5.2.1 DRIVERS 76
5.2.1.1 Growing incidence and prevalence of chronic and genetic diseases 76
FIGURE 26 NUMBER OF PEOPLE 65 OR OLDER WITH ALZHEIMER’S DEMENTIA, 2023 76
5.2.1.2 Rising investments and funding to support genomics projects 77
5.2.1.3 Rising incidence of cancer 78
TABLE 5 CANCER INCIDENCE, 2020 VS. 2040 79
TABLE 6 CANCER PGX-RELATED PHARMACOGENES, DRUG PATHWAYS, AND CANCER DRUGS WITH SIDE EFFECTS 80
5.2.1.4 Increasing collaborations and partnerships between key players and research institutes 80
TABLE 7 COLLABORATIONS AND PARTNERSHIPS BETWEEN KEY PLAYERS AND RESEARCH INSTITUTES 81
5.2.1.5 Increasing focus on translational approach to optimize drug development processes 83
5.2.2 RESTRAINTS 84
5.2.2.1 Challenges in data integration and interpretation 84
5.2.2.2 Issues related to drug response variabilities 84
5.2.3 OPPORTUNITIES 84
5.2.3.1 Use of genomics in specialized/personalized medicine 84
5.2.3.2 AI in pharmacogenomics 85
5.2.3.3 Increasing cost-effectiveness of pharmacogenomics testing 86
5.2.4 CHALLENGES 87
5.2.4.1 Ethical and regulatory hurdles 87
5.2.4.2 Growing concerns related to patient privacy and data access 87
5.3 TECHNOLOGY ANALYSIS 88
5.3.1 SEQUENCING 88
TABLE 8 COMPARISON OF SANGER SEQUENCING AND NGS 88
5.3.2 PCR 89
TABLE 9 COMPARISON OF PCR TECHNOLOGIES 89
5.3.3 MICROARRAY 89
5.4 VALUE CHAIN ANALYSIS 90
FIGURE 27 PHARMACOGENOMICS MARKET: VALUE CHAIN ANALYSIS 92
5.5 SUPPLY CHAIN ANALYSIS 92
FIGURE 28 PHARMACOGENOMICS MARKET: SUPPLY CHAIN ANALYSIS 93
5.6 REGULATORY LANDSCAPE 94
5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
5.6.2 REGULATORY SCENARIO 96
TABLE 14 PHARMACOGENOMICS MARKET: REGULATORY SCENARIO 96
5.7 ECOSYSTEM ANALYSIS 99
5.7.1 PHARMACOGENOMICS PRODUCT VENDORS 99
TABLE 15 PHARMACOGENOMICS PRODUCT VENDORS: ROLE IN ECOSYSTEM 100
5.7.2 PHARMACOGENOMICS SERVICE VENDORS 100
TABLE 16 PHARMACOGENOMICS SERVICE VENDORS: ROLE IN ECOSYSTEM 100
5.7.3 PHARMACOGENOMICS END USERS 101
TABLE 17 PHARMACOGENOMICS END USERS: ROLE IN ECOSYSTEM 101
5.7.4 PHARMACOGENOMICS REGULATORY BODIES 101
TABLE 18 PHARMACOGENOMICS REGULATORY BODIES: ROLE IN ECOSYSTEM 102
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 102
FIGURE 29 REVENUE SHIFT AND NEW REVENUE POCKETS 103
5.9 PRICING ANALYSIS 103
5.9.1 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER 104
TABLE 19 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER (2022) 104
5.9.2 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION 105
TABLE 20 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION (2022) 105
5.9.3 AVERAGE SELLING PRICE TREND ANALYSIS 105
FIGURE 30 GENOME SEQUENCING PRICING TREND 105
5.10 KEY CONFERENCES AND EVENTS IN 2023–2024 106
TABLE 21 PHARMACOGENOMICS MARKET: LIST OF CONFERENCES AND EVENTS 106
5.11 PORTER’S FIVE FORCES ANALYSIS 107
TABLE 22 PHARMACOGENOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 107
5.11.1 THREAT OF NEW ENTRANTS 108
5.11.2 THREAT OF SUBSTITUTES 108
5.11.3 BARGAINING POWER OF SUPPLIERS 108
5.11.4 BARGAINING POWER OF BUYERS 108
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 108
5.12 PATENT ANALYSIS 109
FIGURE 31 PATENT APPLICATIONS FOR PHARMACOGENOMICS MARKET, JANUARY 2013–DECEMBER 2023 109
TABLE 23 INDICATIVE LIST OF PATENTS IN PHARMACOGENOMICS MARKET 109
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 111
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 111
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES 111
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES 111
5.13.2 BUYING CRITERIA FOR PHARMACOGENOMICS MARKET 112
FIGURE 33 BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS 112
TABLE 25 BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS AND SERVICES, BY END USER 113
6 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE 114
6.1 INTRODUCTION 115
TABLE 26 PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
6.2 KITS & REAGENTS 115
TABLE 27 PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 28 PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
TABLE 29 NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 30 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 31 ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 32 LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 33 MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
TABLE 34 MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
6.2.1 SEQUENCING KITS & REAGENTS 119
6.2.1.1 Development of new sequencing technologies to drive market 119
TABLE 35 SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 36 NORTH AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 37 EUROPE: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 38 ASIA PACIFIC: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 39 LATIN AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 40 MIDDLE EAST & AFRICA: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 41 MIDDLE EAST: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 122
6.2.2 PCR KITS & REAGENTS 123
6.2.2.1 Ensures standardized and reliable identification of genetic variants related to drug metabolism 123
TABLE 42 PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 43 NORTH AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 44 EUROPE: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 45 ASIA PACIFIC: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 46 LATIN AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 47 MIDDLE EAST & AFRICA: PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 48 MIDDLE EAST: PCR KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 126
6.2.3 MICROARRAY KITS & REAGENTS 126
6.2.3.1 Cost-effectiveness and high-throughput capabilities to support adoption 126
TABLE 49 MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 50 NORTH AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 51 EUROPE: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 52 ASIA PACIFIC: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 53 LATIN AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 54 MIDDLE EAST & AFRICA: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 55 MIDDLE EAST: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 129
6.2.4 OTHER KITS & REAGENTS 130
TABLE 56 OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 57 NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 58 EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 59 ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 60 LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 61 MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 62 MIDDLE EAST: OTHER KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION) 133
6.3 SERVICES 133
6.3.1 SCALABILITY OF CRO SERVICES ALLOWS TAILORED SOLUTIONS 133
TABLE 63 PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 64 NORTH AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 65 EUROPE: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 66 ASIA PACIFIC: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 67 LATIN AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 68 MIDDLE EAST & AFRICA: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 69 MIDDLE EAST: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 136
7 PHARMACOGENOMICS MARKET, BY TECHNOLOGY 137
7.1 INTRODUCTION 138
TABLE 70 PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 138
7.2 SEQUENCING 138
7.2.1 GROWING ADOPTION OF GENETIC TESTING FOR DIAGNOSIS AND TREATMENT TO DRIVE MARKET 138
TABLE 71 SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION) 139
TABLE 72 NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 73 EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 74 ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 75 LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 76 MIDDLE EAST & AFRICA: SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 77 MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2021–2028 (USD MILLION) 141
7.3 PCR 142
7.3.1 INCREASED USE OF PCR FOR DRUG AND BIOMARKER DISCOVERY TO PROPEL MARKET 142
TABLE 78 PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 143
TABLE 79 NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 80 EUROPE: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 81 ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 82 LATIN AMERICA: PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 83 MIDDLE EAST & AFRICA: PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 145
TABLE 84 MIDDLE EAST: PCR MARKET, BY REGION, 2021–2028 (USD MILLION) 145
7.4 MICROARRAY 146
7.4.1 MICROARRAY HELPS UNDERSTAND GENETIC BASIS OF DRUG METABOLISM 146
TABLE 85 MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 86 NORTH AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 87 EUROPE: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 88 ASIA PACIFIC: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 89 LATIN AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 90 MIDDLE EAST & AFRICA: MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION) 149
TABLE 91 MIDDLE EAST: MICROARRAY MARKET, BY REGION, 2021–2028 (USD MILLION) 149
7.5 OTHER TECHNOLOGIES 149
TABLE 92 OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 150
TABLE 93 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 94 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 95 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 96 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 97 MIDDLE EAST & AFRICA: OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 152
TABLE 98 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION) 152
8 PHARMACOGENOMICS MARKET, BY APPLICATION 153
8.1 INTRODUCTION 154
TABLE 99 PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 154
8.2 PERSONALIZED MEDICINE 154
8.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET 154
TABLE 100 PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 101 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 102 EUROPE: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 103 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 104 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 105 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 106 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021–2028 (USD MILLION) 158
8.3 CLINICAL RESEARCH 158
8.3.1 GROWING NUMBER OF CLINICAL TRIALS FOR PHARMACOGENOMICS TO DRIVE MARKET 158
TABLE 107 PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION) 159
TABLE 108 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 109 EUROPE: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 160
TABLE 110 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 111 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 112 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION) 162
TABLE 113 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION) 162
8.4 DRUG DISCOVERY & PRECLINICAL DEVELOPMENT 162
8.4.1 INCREASING APPLICATIONS OF PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH 162
TABLE 114 PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 115 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 163
TABLE 116 EUROPE: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 117 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 118 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 119 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 165
TABLE 120 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021–2028 (USD MILLION) 165
9 PHARMACOGENOMICS MARKET, BY DISEASE AREA 166
9.1 INTRODUCTION 167
TABLE 121 PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 167
9.2 CANCER 167
9.2.1 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET 167
TABLE 122 PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 168
TABLE 123 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 124 EUROPE: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 125 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 169
TABLE 126 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 170
TABLE 127 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 170
TABLE 128 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 170
9.3 CARDIOVASCULAR DISEASE 171
9.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH 171
TABLE 129 PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION) 171
TABLE 130 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 131 EUROPE: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 132 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 133 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 134 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION) 174
TABLE 135 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021–2028 (USD MILLION) 174
9.4 NEUROLOGICAL DISORDERS 174
9.4.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 174
TABLE 136 PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 137 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 138 EUROPE: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 139 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 140 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 141 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 177
TABLE 142 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION) 177
9.5 OTHER DISEASE AREAS 178
TABLE 143 PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION) 178
TABLE 144 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 179
TABLE 145 EUROPE: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 179
TABLE 146 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 147 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 148 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION) 181
TABLE 149 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION) 181
10 PHARMACOGENOMICS MARKET, BY END USER 182
10.1 INTRODUCTION 183
TABLE 150 PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 183
10.2 ACADEMIC & RESEARCH INSTITUTES 183
10.2.1 INCREASING RESEARCH ACTIVITIES AND FUNDING TO DRIVE GROWTH 183
TABLE 151 PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 184
TABLE 152 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 153 EUROPE: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 154 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 185
TABLE 155 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 186
TABLE 156 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 186
TABLE 157 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 186
10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 187
10.3.1 GROWING STRATEGIC ALLIANCES FOR DRUG DEVELOPMENT AND PERSONALIZED MEDICINE TO PROPEL MARKET 187
TABLE 158 PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 188
TABLE 159 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 160 EUROPE: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 189
TABLE 161 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 189
TABLE 162 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 163 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 190
TABLE 164 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 190
10.4 CONTRACT RESEARCH ORGANIZATIONS 191
10.4.1 INCREASING OUTSOURCING TREND IN GENOMICS FIELD TO PROPEL MARKET 191
TABLE 165 PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 191
TABLE 166 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 167 EUROPE: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 192
TABLE 168 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 169 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 170 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 194
TABLE 171 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 194
11 PHARMACOGENOMICS MARKET, BY REGION 195
11.1 INTRODUCTION 196
TABLE 172 PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 196
11.2 NORTH AMERICA 196
FIGURE 34 NORTH AMERICA: PHARMACOGENOMICS MARKET SNAPSHOT 197
TABLE 173 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 197
TABLE 174 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 198
TABLE 175 NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 176 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 199
TABLE 177 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 199
TABLE 178 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 200
TABLE 179 NORTH AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 200
11.2.1 US 201
11.2.1.1 US dominates North American pharmacogenomics market 201
TABLE 180 US: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 202
TABLE 181 US: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 182 US: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 202
TABLE 183 US: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
TABLE 184 US: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 203
TABLE 185 US: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 204
11.2.2 CANADA 204
11.2.2.1 Growing research activities in genomics field to drive market 204
TABLE 186 CANADA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 205
TABLE 187 CANADA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 188 CANADA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 206
TABLE 189 CANADA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 206
TABLE 190 CANADA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 207
TABLE 191 CANADA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 207
11.2.3 RECESSION IMPACT ON NORTH AMERICAN PHARMACOGENOMICS MARKET 208
11.3 EUROPE 208
TABLE 192 EUROPE: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 193 EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 209
TABLE 194 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 195 EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 210
TABLE 196 EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211
TABLE 197 EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 211
TABLE 198 EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 212
11.3.1 GERMANY 212
11.3.1.1 Growing strategic alliances among industry players and research institutes to support market growth 212
TABLE 199 GERMANY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 213
TABLE 200 GERMANY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 201 GERMANY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 214
TABLE 202 GERMANY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 214
TABLE 203 GERMANY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 215
TABLE 204 GERMANY: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 215
11.3.2 UK 216
11.3.2.1 Increasing government funding for genomics projects to propel market 216
TABLE 205 UK: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 217
TABLE 206 UK: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 207 UK: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 218
TABLE 208 UK: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 218
TABLE 209 UK: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 219
TABLE 210 UK: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 219
11.3.3 FRANCE 219
11.3.3.1 Increasing government initiatives to boost market growth 219
TABLE 211 FRANCE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 220
TABLE 212 FRANCE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 220
TABLE 213 FRANCE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 221
TABLE 214 FRANCE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 221
TABLE 215 FRANCE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 222
TABLE 216 FRANCE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 222
11.3.4 ITALY 223
11.3.4.1 Favorable funding programs to support market growth 223
TABLE 217 ITALY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 223
TABLE 218 ITALY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 219 ITALY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 224
TABLE 220 ITALY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 225
TABLE 221 ITALY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 225
TABLE 222 ITALY: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 226
11.3.5 SPAIN 226
11.3.5.1 Government funding for research in pharmacogenomics and precision medicine to drive market 226
TABLE 223 SPAIN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 227
TABLE 224 SPAIN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 225 SPAIN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 228
TABLE 226 SPAIN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 228
TABLE 227 SPAIN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 228
TABLE 228 SPAIN: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 229
11.3.6 REST OF EUROPE 229
TABLE 229 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 230
TABLE 230 REST OF EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 231 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 231
TABLE 232 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 231
TABLE 233 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 232
TABLE 234 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 232
11.3.7 RECESSION IMPACT ON EUROPEAN PHARMACOGENOMICS MARKET 233

11.4 ASIA PACIFIC 233
FIGURE 35 ASIA PACIFIC: PHARMACOGENOMICS MARKET SNAPSHOT 234
TABLE 235 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 235
TABLE 236 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 235
TABLE 237 ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 236
TABLE 238 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 236
TABLE 239 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 237
TABLE 240 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 237
TABLE 241 ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 238
11.4.1 CHINA 238
11.4.1.1 Increasing research and development spending to support market growth 238
TABLE 242 CHINA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 239
TABLE 243 CHINA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 244 CHINA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 240
TABLE 245 CHINA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 240
TABLE 246 CHINA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 241
TABLE 247 CHINA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 241
11.4.2 JAPAN 242
11.4.2.1 Growing focus on development of new pharmacogenomic services to drive market 242
TABLE 248 JAPAN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 243
TABLE 249 JAPAN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 250 JAPAN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 243
TABLE 251 JAPAN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 244
TABLE 252 JAPAN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 244
TABLE 253 JAPAN: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 244
11.4.3 INDIA 245
11.4.3.1 Growing prevalence of chronic diseases to drive market 245
TABLE 254 INDIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 246
TABLE 255 INDIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 246
TABLE 256 INDIA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 246
TABLE 257 INDIA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 247
TABLE 258 INDIA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 247
TABLE 259 INDIA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 248
11.4.4 AUSTRALIA 248
11.4.4.1 Increase in research activities to propel market 248
TABLE 260 AUSTRALIA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 249
TABLE 261 AUSTRALIA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 262 AUSTRALIA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 250
TABLE 263 AUSTRALIA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 250
TABLE 264 AUSTRALIA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 251
TABLE 265 AUSTRALIA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 251
11.4.5 SOUTH KOREA 251
11.4.5.1 Increasing investments in genomics research to drive market 251
TABLE 266 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 252
TABLE 267 SOUTH KOREA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 252
TABLE 268 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 253
TABLE 269 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 253
TABLE 270 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 254
TABLE 271 SOUTH KOREA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 254
11.4.6 REST OF ASIA PACIFIC 254
TABLE 272 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 255
TABLE 273 REST OF ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 256
TABLE 274 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 256
TABLE 275 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 257
TABLE 276 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 257
TABLE 277 REST OF ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 258
11.4.7 RECESSION IMPACT ON ASIA PACIFIC PHARMACOGENOMICS MARKET 258
11.5 LATIN AMERICA 259
TABLE 278 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 259
TABLE 279 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 260
TABLE 280 LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 260
TABLE 281 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 261
TABLE 282 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 261
TABLE 283 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 262
TABLE 284 LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 262
11.5.1 BRAZIL 262
11.5.1.1 Increasing investments in biopharmaceutical research to propel market 262
TABLE 285 BRAZIL: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 263
TABLE 286 BRAZIL: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 263
TABLE 287 BRAZIL: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 264
TABLE 288 BRAZIL: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 264
TABLE 289 BRAZIL: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 265
TABLE 290 BRAZIL: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 265
11.5.2 MEXICO 266
11.5.2.1 Increasing genomics research activities to drive market 266
TABLE 291 MEXICO: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 266
TABLE 292 MEXICO: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 267
TABLE 293 MEXICO: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 267
TABLE 294 MEXICO: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 268
TABLE 295 MEXICO: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 268
TABLE 296 MEXICO: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 269
11.5.3 REST OF LATIN AMERICA 269
TABLE 297 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 269
TABLE 298 REST OF LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 270
TABLE 299 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 270
TABLE 300 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 271
TABLE 301 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 271
TABLE 302 REST OF LATIN AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 272
11.5.4 RECESSION IMPACT ON LATIN AMERICAN PHARMACOGENOMICS MARKET 272
11.6 MIDDLE EAST & AFRICA 273
TABLE 303 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 273
TABLE 304 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 273
TABLE 305 MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 274
TABLE 306 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 274
TABLE 307 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 275
TABLE 308 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 275
TABLE 309 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 276
11.6.1 MIDDLE EAST 276
TABLE 310 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY REGION, 2021–2028 (USD MILLION) 276
TABLE 311 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 277
TABLE 312 MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 313 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 278
TABLE 314 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 278
TABLE 315 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 279
TABLE 316 MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 279
11.6.1.1 GCC countries 280
11.6.1.1.1 Increasing government initiatives for pharmacogenomics to propel market 280
TABLE 317 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 280
TABLE 318 GCC COUNTRIES: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 281
TABLE 319 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 281
TABLE 320 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 282
TABLE 321 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 282
TABLE 322 GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 283
11.6.1.2 Rest of Middle East 283
TABLE 323 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 283
TABLE 324 REST OF MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 284
TABLE 325 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 284
TABLE 326 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 285
TABLE 327 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 285
TABLE 328 REST OF MIDDLE EAST: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 286
11.6.2 AFRICA 286
11.6.2.1 Growing prevalence of HIV & cancer to drive market 286
TABLE 329 AFRICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 287
TABLE 330 AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 331 AFRICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 288
TABLE 332 AFRICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 288
TABLE 333 AFRICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 288
TABLE 334 AFRICA: PHARMACOGENOMICS MARKET, BY END USER, 2021–2028 (USD MILLION) 289
11.6.3 RECESSION IMPACT ON MIDDLE EAST & AFRICA PHARMACOGENOMICS MARKET 289
12 COMPETITIVE LANDSCAPE 290
12.1 OVERVIEW 290
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 290
FIGURE 36 PHARMACOGENOMICS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 291
12.3 REVENUE SHARE ANALYSIS 292
FIGURE 37 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PHARMACOGENOMICS MARKET, 2018–2022 (USD MILLION) 292
12.4 MARKET SHARE ANALYSIS 292
FIGURE 38 PHARMACOGENOMICS MARKET SHARE, BY KEY PLAYER (2022) 293
TABLE 335 PHARMACOGENOMICS MARKET: INTENSITY OF COMPETITIVE RIVALRY 293
12.5 COMPANY EVALUATION MATRIX 295
12.5.1 STARS 295
12.5.2 EMERGING LEADERS 296
12.5.3 PERVASIVE PLAYERS 296
12.5.4 PARTICIPANTS 296
FIGURE 39 PHARMACOGENOMICS MARKET: COMPANY EVALUATION MATRIX (2022) 296
12.5.5 COMPANY FOOTPRINT 297
TABLE 336 PRODUCT & SERVICE FOOTPRINT 298
TABLE 337 REGIONAL FOOTPRINT 299
12.6 STARTUP/SME EVALUATION MATRIX 300
12.6.1 PROGRESSIVE COMPANIES 300
12.6.2 RESPONSIVE COMPANIES 300
12.6.3 DYNAMIC COMPANIES 300
12.6.4 STARTING BLOCKS 300
FIGURE 40 PHARMACOGENOMICS MARKET: STARTUP/SME EVALUATION MATRIX (2022) 301
12.7 COMPETITIVE BENCHMARKING 302
TABLE 338 PHARMACOGENOMICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 302
TABLE 339 PHARMACOGENOMICS MARKET: PRODUCT & SERVICE AND REGIONAL FOOTPRINT OF KEY STARTUPS/SMES 304
12.8 COMPETITIVE SCENARIO 305
TABLE 340 PHARMACOGENOMICS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–DECEMBER 2023 305
TABLE 341 PHARMACOGENOMICS MARKET: DEALS, JANUARY 2020−DECEMBER 2023 306
TABLE 342 PHARMACOGENOMICS MARKET: OTHER DEVELOPMENTS, JANUARY 2020− DECEMBER 2023 307
13 COMPANY PROFILES 308
13.1 KEY PLAYERS 308
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1.1 ILLUMINA, INC. 308
TABLE 343 ILLUMINA, INC.: BUSINESS OVERVIEW 308
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 309
13.1.2 THERMO FISHER SCIENTIFIC INC. 315
TABLE 344 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 315
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 316
13.1.3 F. HOFFMANN-LA ROCHE LTD. 320
TABLE 345 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 320
FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 321
13.1.4 QIAGEN 325
TABLE 346 QIAGEN: BUSINESS OVERVIEW 325
FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2022) 326
13.1.5 DANAHER CORPORATION 333
TABLE 347 DANAHER CORPORATION: BUSINESS OVERVIEW 333
FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 334
13.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 337
TABLE 348 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 337
FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022) 338
13.1.7 EUROFINS SCIENTIFIC 340
TABLE 349 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 340
FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 341
13.1.8 CHARLES RIVER LABORATORIES 343
TABLE 350 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 343
FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022) 344
13.1.9 BIO-RAD LABORATORIES, INC. 346
TABLE 351 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 346
FIGURE 49 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 347
13.1.10 AGILENT TECHNOLOGIES, INC. 349
TABLE 352 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 349
FIGURE 50 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 350
13.1.11 BECTON, DICKINSON AND COMPANY 354
TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 354
FIGURE 51 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 355
13.1.12 REVVITY 358
TABLE 354 REVVITY: BUSINESS OVERVIEW 358
FIGURE 52 REVVITY: COMPANY SNAPSHOT (2022) 359
13.1.13 IQVIA, INC. 362
TABLE 355 IQVIA, INC.: BUSINESS OVERVIEW 362
FIGURE 53 IQVIA, INC.: COMPANY SNAPSHOT (2022) 363
13.1.14 MESA LABS, INC. 365
TABLE 356 MESA LABORATORIES, INC.: BUSINESS OVERVIEW 365
FIGURE 54 MESA LABS, INC.: COMPANY SNAPSHOT (2022) 366
13.1.15 MEDPACE, INC. 368
TABLE 357 MEDPACE, INC.: BUSINESS OVERVIEW 368
FIGURE 55 MEDPACE, INC.: COMPANY SNAPSHOT (2022) 368
13.1.16 MGI TECH CO., LTD. 370
TABLE 358 MGI TECH CO., LTD.: BUSINESS OVERVIEW 370
FIGURE 56 MGI TECH CO., LTD.: COMPANY SNAPSHOT (2022) 370
13.2 OTHER PLAYERS 374
13.2.1 PACBIO 374
TABLE 359 PACBIO: COMPANY OVERVIEW 374
13.2.2 TAKARA BIO INC. 375
TABLE 360 TAKARA BIO INC.: COMPANY OVERVIEW 375
13.2.3 NEW ENGLAND BIOLABS 377
TABLE 361 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 377
13.2.4 BGI 378
TABLE 362 BGI: COMPANY OVERVIEW 378
13.2.5 NOVOGENE CO., LTD. 379
TABLE 363 NOVOGENE CO., LTD.: COMPANY OVERVIEW 379
13.2.6 SOPHIA GENETICS 380
TABLE 364 SOPHIA GENETICS: COMPANY OVERVIEW 380
13.2.7 FIOS GENOMICS 381
TABLE 365 FIOS GENOMICS: COMPANY OVERVIEW 381
13.2.8 PERSONALIS, INC. 382
TABLE 366 PERSONALIS, INC.: COMPANY OVERVIEW 382
13.2.9 NEOGENOMICS LABORATORIES 383
TABLE 367 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW 383
13.2.10 BIOAI HEALTH INC. 385
TABLE 368 BIOAI HEALTH INC.: COMPANY OVERVIEW 385
13.2.11 MACROGEN, INC. 386
TABLE 369 MACROGEN, INC.: COMPANY OVERVIEW 386
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX 387
14.1 DISCUSSION GUIDE 387
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 393
14.3 CUSTOMIZATION OPTIONS 395
14.4 RELATED REPORTS 395
14.5 AUTHOR DETAILS 396

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 等温核酸増幅技術（INAAT）のグローバル市場予測（～2028）：アッセイ・キット・試薬、システム
  • ゲノミクスにおける人工知能（AI）のグローバル市場予測（～2028）：ソフトウェア、サービス
  • 外断熱工法（EIFS）のグローバル市場予測（～2028）：PB、PM
  • メタロセンポリエチレン（mPE）のグローバル市場予測（～2028）：フィルム、シート、射出成形、押出コーティング
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(BT8937-24 )"ファーマコゲノミクス（PGx）のグローバル市場予測（～2028）：キット、試薬" (英文：Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。